» Articles » PMID: 12594562

Proton Magnetic Resonance Spectroscopy ((1)H MRS) of Human Brain Tumours: Assessment of Differences Between Tumour Types and Its Applicability in Brain Tumour Categorization

Overview
Journal Eur Radiol
Specialty Radiology
Date 2003 Feb 21
PMID 12594562
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Our objective was to evaluate the usefulness of proton magnetic resonance spectroscopy ((1)H MRS) in categorizing brain tumours. In vivo single-voxel (1)H MRS at an echo time of 136 ms was performed in 108 patients with brain neoplasms that included 29 meningiomas (MEN), 15 low-grade astrocytomas (LGA), 12 anaplastic astrocytomas (AA), 25 glioblastomas (GBM) and 27 metastases (MET). Time-domain fitted areas of nine resonances were evaluated in all spectra. Twenty-five additional tumours were prospectively included as independent test set. Differences in at least two resonances were found in all pairwise comparisons of tumour groups except in GBM vs MET. Large lipid resonance at 1.30 ppm was found to be characteristic of GBM and MET, and alanine was characteristic of MEN. Significant differences were found between LGA and AA in choline-containing compounds and total creatine resonances. When implemented in a stepwise algorithm, these findings correctly classified 84% (21 of 25) tumours in the independent test set. Some additional utility was found in glycine/myo-inositol at 3.55 ppm for bilateral differentiation between GBM and MET (9 of 11, 82% correct classification in the test set). (1)H MRS provides useful information to categorize the most common brain tumours that can be implemented in clinical practice with satisfactory results.

Citing Articles

Advances in imaging modalities for spinal tumors.

Takamiya S, Malvea A, Ishaque A, Pedro K, Fehlings M Neurooncol Adv. 2024; 6(Suppl 3):iii13-iii27.

PMID: 39430391 PMC: 11485884. DOI: 10.1093/noajnl/vdae045.


Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors.

Majos C, Pons-Escoda A, Naval P, Guell A, Lucas A, Vidal N Eur Radiol. 2023; 34(4):2174-2182.

PMID: 37740778 DOI: 10.1007/s00330-023-10138-9.


In vivo Human MR Spectroscopy Using a Clinical Scanner: Development, Applications, and Future Prospects.

Tomiyasu M, Harada M Magn Reson Med Sci. 2022; 21(1):235-252.

PMID: 35173095 PMC: 9199975. DOI: 10.2463/mrms.rev.2021-0085.


Utility of 3T single-voxel proton MR spectroscopy for differentiating intracranial meningiomas from intracranial enhanced mass lesions.

Matsusue E, Inoue C, Tabuchi S, Yoshioka H, Nagao Y, Matsumoto K Acta Radiol Open. 2021; 10(4):20584601211009472.

PMID: 34211737 PMC: 8215334. DOI: 10.1177/20584601211009472.


Quantitative metabolic characteristics in the peritumoral region of gliomas at 7T.

Yan G, Yi M, Li S, Yang L, Dai Z, Xuan Y Technol Health Care. 2021; 29(S1):509-517.

PMID: 33682787 PMC: 8150443. DOI: 10.3233/THC-218048.